TargetBeta
CTLA4
cytotoxic T-lymphocyte associated protein 4 · also CD152, CD, GSE, CTLA-4 · CD molecules
15 programs in company-led studies act on CTLA4, from 14 companies: 8 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| cadonilimabrule | Akeso | phase 3 | 4522 running | PDCD1 | NCIt |
| tremelimumabrule | AstraZeneca | phase 3 | 4718 running | – | NCIt |
| volrustomig | AstraZeneca | phase 3 | 1917 running | PDCD1 | a judged reading |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 1615 running | – | NCIt |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 2214 running | PDCD1 | NCIt |
| gotistobartrule | OncoC4 | phase 3 | 55 running | – | NCIt |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 142 running | CD274 | NCIt |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 112 running | – | NCIt |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | HC Biopharma | phase 2 | 22 running | PDCD1, VEGFA | NCIt |
| GB268rule | Eddingpharm (Zhuhai) | phase 2 | 22 running | – | the studies' text |
| LM-168 | Sino Biopharmaceutical | phase 2 | 22 running | – | the company's pipeline |
| zalifrelimabrule | Agenus | phase 2 | 61 running | – | NCIt |
| porustobartrule | Harbour BioMed (Guangzhou) | phase 2 | 51 running | – | NCIt |
| lorigerlimabrule | MacroGenics | phase 2 | 41 running | PDCD1 | NCIt |
| CS2009rule | CStone Pharmaceuticals | phase 2 | 11 running | VEGFA | the studies' text |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 9 programs
- Uterine Cervical Neoplasms, 5 programs
- Carcinoma, Hepatocellular, 4 programs
- Colorectal Neoplasms, 4 programs
- Carcinoma, Renal Cell, 3 programs
- Melanoma, 3 programs
- Colonic Neoplasms, 2 programs
- Prostatic Neoplasms, 2 programs
- Small Cell Lung Carcinoma, 2 programs
- Squamous Cell Carcinoma of Head and Neck, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026cadonilimab · Akeso · phase 3 · NCT06341335
- Nov 30, 2026tremelimumab · AstraZeneca · phase 3 · NCT07081633
- Nov 30, 2026gotistobart · OncoC4 · phase 3 · NCT05682443
- Dec 30, 2026Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010 · HC Biopharma · phase 2 · NCT07169552
- Jan 2027CS2009 · CStone Pharmaceuticals · phase 2 · NCT06741644
- Jan 29, 2027volrustomig · AstraZeneca · phase 3 · NCT07000149
- Mar 2027GB268 · Eddingpharm (Zhuhai) · phase 2 · NCT06934616
- Jun 2027Iparomlimab/Tuvonralimab · Qilu Pharmaceutical · phase 3 · NCT07272590
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.